Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

Diabetes Ther. 2015 Sep;6(3):239-56. doi: 10.1007/s13300-015-0127-x. Epub 2015 Aug 14.


Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.

Keywords: GLP-1 RAs; Glucagon-like peptide-1 receptor agonists; Incretin; Type 2 diabetes mellitus.